Sector Investors News and Insights

Immutep Limited

Immutep has announced a partnership with MSD to assess the effectiveness of Efti alongside KEYTRUDA in a crucial Phase III study.

Phase III collaboration will assess the effectiveness of efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III…

Immutep has announced a partnership with MSD to assess the effectiveness of Efti alongside KEYTRUDA in a crucial Phase III study. Read More »

,

Immutep has announced a clinical collaboration with MSD to assess Efti in combination with KEYTRUDA in a pivotal Phase III trial.

Phase III collaboration will assess efti with KEYTRUDA and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) as part of the TACTI-004 Phase III study.

Immutep has announced a clinical collaboration with MSD to assess Efti in combination with KEYTRUDA in a pivotal Phase III trial. Read More »

,
Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com